medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2025-14-31-37medalphabet-4465Research ArticleСтатьиЛучевые повреждения мочевого пузыря при раке предстательной железы: обзор литературыLate urinary toxicity following radiation in prostate cancer: literature reviewhttps://orcid.org/0000-0002-9676-1802МонаковД. М.MonakovD. M.

Дмитрий Михайлович Монаков, к. м. н., старший научный сотрудник, доцент

отдел онкоурологии; кафедра урологии и оперативной нефрологии с курсом онкоурологии

Москва

РИНЦ Author ID 995385

Dmitry M. Monakov, PhD Med, senior researcher, associate professor

Dept of urology and surgical nephrology with a course in oncourology

Moscow

РИНЦ Author ID 995385

gvkg-monakov@mail.ruhttps://orcid.org/0000-0001-6481-1724КукошМ. Ю.KukoshM. Yu.

Мария Юрьевна Кукош, к. м. н., доцент, старший научный сотрудник, врач-онколог

кафедра онкологии и гематологии

Москва; Обнинск

РИНЦ AuthorID 824956

Maria Yu. Kukosh, PhD Med, associate professor,  senior researcher, medical oncologist

Dept of Oncology and Hematology

Moscow; Obninsk

РИНЦ AuthorID 824956

manja70@inbox.ruЗимовецО. М.ZimovetsO. M.

Оксана Михайловна Зимовец, клинический ординатор по специальности«Урология»

Москва

Oksana M. Zimovets, resident in the specialty “Urology”

Moscow

zimovetsom@mail.ruhttps://orcid.org/0000-0002-5160-925XГрицкевичА. А.GritskevichA. A.

Александр Анатольевич Грицкевич, д. м. н., зав. отделением, проф.

отделение онкоурологии и урологии; кафедра урологии и оперативной нефрологии с курсом онкоурологии

Москва

РИНЦ AuthorID:816947

Alexandr A. Gritskevich, DM Sci (habil.), head of Dept, professor

Dept of oncourology and urology; Dept of Urology and Surgical Nephrology with a Course in Oncourology

Moscow

РИНЦ AuthorID:816947

grekaa@mail.ruhttps://orcid.org/0000-0001-5347-8364БогдановА. Б.BogdanovA. B.

Андрей Борисович Богданов, к. м. н., врач-уролог, доцент

урологическое отделение; кафедра урологии и хирургической андрологии

Москва

РИНЦ AuthorID 742456

Andrey B. Bogdanov, PhD Med, urologist, associate professor

Urology Dept; Dept of Urology and Surgical Andrology

Moscow

bogdanovab@botkinmoscow.ruhttps://orcid.org/0000-0002-0042-1150Тер-ОванесовМ. Д.Ter-OvanesovM. D.

Михаил Дмитриевич Тер-Ованесов, д. м. н., проф., зав. кафедрой

кафедра онкологии и гематологии

Москва

РИНЦ AuthorID 698259

Mikhail D. Ter-Ovanesov, DM Sci (habil.), professor, head of Dept

Dept of Oncology and Hematology

Moscow

РИНЦ AuthorID 698259

termd@yandex.ruФГБУ «Национальный медицинский исследовательский центр им. А. В. Вишневского» Минздрава России; ФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН)РоссияVishnevsky National Medical Research Center of Surgery; Peoples’ Friendship University named after Patrice LumumbaRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН); Медицинский радиологический научный центр им. А. Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России; ООО «МЕЛАНОМА ЮНИТ»РоссияPeoples’ Friendship University named after Patrice Lumumba; Medical Radiological Scientific Center named after A. F. Tsyba – a branch of the National Medical Research Center of Radiology; MELANOMA UNIT СLCRussian FederationФГБУ «Национальный медицинский исследовательский центр им. А. В. Вишневского» Минздрава РоссииРоссияVishnevsky National Medical Research Center of SurgeryRussian FederationГБУЗ «Московский многопрофильный научно-клинический центр им. С. П. Боткина ДЗМ»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования»РоссияRussia Moscow Multidisciplinary Scientific and Clinical Center named after S. P. Botkin; Russian Medical Academy of Continuing Professional EducationRussian FederationФГАОУ ВО «Российский университет дружбы народов имени Патриса Лумумбы» (РУДН)РоссияPeoples’ Friendship University named after Patrice LumumbaRussian Federation202526072025014Диагностика и онкотерапия (2)3137Copyright © Монаков Д.М., Кукош М.Ю., Зимовец О.М., Грицкевич А.А., Богданов А.Б., Тер-Ованесов М.Д., 20252025Монаков Д.М., Кукош М.Ю., Зимовец О.М., Грицкевич А.А., Богданов А.Б., Тер-Ованесов М.Д.Monakov D.M., Kukosh M.Y., Zimovets O.M., Gritskevich A.A., Bogdanov A.B., Ter-Ovanesov M.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/4465   Введение

   Введение. Радиационные повреждения мочевого пузыря – одно из наиболее распространенных осложнений лучевой терапии злокачественных новообразований малого таза.

   Материалы и методы

   Материалы и методы. Проведены поиск, анализ и систематизация релевантных публикаций в базах данных e.Library.ru, cyberleninka.ru, PubMed. Отобрано 65 статей, которые включены в настоящий обзор.

   Результаты и обсуждение. Приведены данные об эпидемиологии, факторах риска, патогенезе, профилактике, диагностике и лечении лучевых повреждений мочевого пузыря.

   Выводы

   Выводы. Гипербарическая оксигенация, внутрипузырные инстилляции глюкозоаминогликановой кислоты и хондроитина сульфата, а также трансуретральная фульгурация остаются наиболее эффективными методами лечения лучевых повреждений мочевого пузыря.

   Introduction

   Introduction. Radiation damage to the bladder is one of the most common complications of radiation therapy for pelvic malignancies.

   Materials and methods

   Materials and methods. The search, analysis and systematization of relevant publications in databases were carried out. e.Library.ru, cyberleninka.ru, PubMed. 64 articles were selected, which are included in this review.

   Results and discussion. Data on epidemiology, risk factors, pathogenesis, prevention, diagnosis, and treatment of radiation damage to the bladder are presented.

   Conclusions

   Conclusions. Hyperbaric oxygenation, intravesical instillation of glycosaminoglycan acid and chondroitin sulfate, as well as transurethral fulguration remain the most effective methods of treating radiation damage to the bladder.

рак предстательной железылучевая терапияпоздняя лучевая токсичностьпоздний лучевой циститprostate cancerradiation therapylate radiation toxicitylate radiation cystitisReferencesРак предстательной железы. Клинические рекомендации Министерства здравоохранения РФ. URL: https://cr.minzdrav.gov.ru/preview-cr/12_3 (дата обращения: 20. 12. 2024).Prostate cancer. Clinical recommendations of the Ministry of Health of the Russian Federation. Available on: https://cr.minzdrav.gov.ru/preview-cr/12_3 (Cited 2024 Dec 12). (In Russ.).NCCN guidelines version 1.2025. Prostate cancer. Available from: www.nccn.org/patients. Cited 2020 Dec 20.NCCN guidelines version 1.2025. Prostate cancer. Available from: www.nccn.org/patients. Cited 2020 Dec 20.EAU guidelines. Prostate cancer. Available from: https://uroweb.org/guidelines/prostate-cancer.EAU guidelines. Prostate cancer. Available from: https://uroweb.org/guidelines/prostate-cancer.Lee V, An Y, Park HS. et al. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU Int. 2022; 130 (2): 208–216. doi: 10.1111/bju.15650Lee V, An Y, Park HS. et al. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU Int. 2022; 130 (2): 208–216. doi: 10.1111/bju.15650Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001; 40 (2): 111–23. doi: 10.1159/000049760Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001; 40 (2): 111–23. doi: 10.1159/000049760Halperin E. C., Perez С. А., Brady L. W. Perez and Brady’s principles and practice of radiation oncology. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2008. 2106 p.Halperin E. C., Perez С. А., Brady L. W. Perez and Brady’s principles and practice of radiation oncology. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2008. 2106 p.Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database of Systematic Reviews. 2002; 3: IDCD 001773.Denton AS, Clarke NW, Maher EJ. Non-surgical interventions for late radiation cystitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database of Systematic Reviews. 2002; 3: IDCD 001773.Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360–3016(95)00060-CCox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31 (5): 1341–6. doi: 10.1016/0360–3016(95)00060-CFuentes-Raspall R, Inoriza JM, Rosello-Serrano A. et al. Late rectal and bladder toxicity following radiation therapy for prostate cancer: predictive factors and treatment results. Rep Pract Oncol Radiother. 2013; 18 (5): 298–303. doi: 10.1016/j.rpor.2013.05.006Fuentes-Raspall R, Inoriza JM, Rosello-Serrano A. et al. Late rectal and bladder toxicity following radiation therapy for prostate cancer: predictive factors and treatment results. Rep Pract Oncol Radiother. 2013; 18 (5): 298–303. doi: 10.1016/j.rpor.2013.05.006Detti B, Baki M, Becherini C, Saieva C. et al. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience. Radiol Med. 2019; 124 (5): 422–431. doi: 10.1007/s11547-018-0977-1Detti B, Baki M, Becherini C, Saieva C. et al. High-dose intensity-modulated radiation therapy as primary treatment of prostate cancer: genitourinary/gastrointestinal toxicity and outcomes, a single-institution experience. Radiol Med. 2019; 124 (5): 422–431. doi: 10.1007/s11547-018-0977-1Anderson J.F., Swanson D.A., Levy L.B. et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009; 74 (3): 601–5. doi: 10.1016/j.urology.2009.04.060Anderson J.F., Swanson D.A., Levy L.B. et al. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology. 2009; 74 (3): 601–5. doi: 10.1016/j.urology.2009.04.060Hebert KJ, Matta R, Fendereski K. et al. Genitourinary radiation injury following prostate cancer treatment: assessment of cost and health care system burden. Urology. 2023; 179: 166–173. doi: 10.1016/j.urology.2023.03.056Hebert KJ, Matta R, Fendereski K. et al. Genitourinary radiation injury following prostate cancer treatment: assessment of cost and health care system burden. Urology. 2023; 179: 166–173. doi: 10.1016/j.urology.2023.03.056Бердичевский В. Б., Гутрова Е. И., Налетов А. А. и др. Радионуклидиндуцированный цистит. Современный взгляд на проблему. Академический журнал Западной Сибири. 2020; 16 (5 (88)): 45–47.Berdichevsky V. B., Gutrova E. I., Naletov A. A. and others. Radionuclide-induced cystitis. A modern view of the problem. Academic Journal of Western Siberia. 2020; 16 (5 (88)): 45–47. (In Russ.).Bologna E, Licari LC, Franco A. et al. Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: analysis from a national database. Urology. 2024; 191: 86–92. doi: 10.1016/j.urology.2024.04.035Bologna E, Licari LC, Franco A. et al. Incidence and management of radiation cystitis after pelvic radiotherapy for prostate cancer: analysis from a national database. Urology. 2024; 191: 86–92. doi: 10.1016/j.urology.2024.04.035Lonergan PE, Baskin A, Greenberg SA. et al. The Long-term incidence and quality of life outcomes associated with treatment-related toxicities of external beam radiotherapy for prostate cancer. Urology. 2023; 178: 114–119. doi: 10.1016/j.urology.2023.05.012Lonergan PE, Baskin A, Greenberg SA. et al. The Long-term incidence and quality of life outcomes associated with treatment-related toxicities of external beam radiotherapy for prostate cancer. Urology. 2023; 178: 114–119. doi: 10.1016/j.urology.2023.05.012Sanguedolce F, Sancho Pardo G. et al. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate Int. 2021; 9 (1): 48–53. doi: 10.1016/j.prnil.2020.07.006Sanguedolce F, Sancho Pardo G. et al. Radiation-induced haemorrhagic cystitis after prostate cancer radiotherapy: factors associated to hospitalization and treatment strategies. Prostate Int. 2021; 9 (1): 48–53. doi: 10.1016/j.prnil.2020.07.006Afonso-João D, Pacheco-Figueiredo L, Antunes-Lopes T. et al. Cumulative incidence and predictive factors of radiation cystitis in patients with localized prostate cancer. Actas Urol Esp (Engl Ed). 2018; 42 (4): 256–261. doi: 10.1016/j.acuro.2017.06.009Afonso-João D, Pacheco-Figueiredo L, Antunes-Lopes T. et al. Cumulative incidence and predictive factors of radiation cystitis in patients with localized prostate cancer. Actas Urol Esp (Engl Ed). 2018; 42 (4): 256–261. doi: 10.1016/j.acuro.2017.06.009Makino K, Sato Y, Takenaka R. et al. Cumulative incidence and clinical risk factors of radiation cystitis after radiotherapy for prostate cancer. Urol Int. 2023; 107 (5): 440–446. doi: 10.1159/000521723Makino K, Sato Y, Takenaka R. et al. Cumulative incidence and clinical risk factors of radiation cystitis after radiotherapy for prostate cancer. Urol Int. 2023; 107 (5): 440–446. doi: 10.1159/000521723Doiron RC, Witten J, Rourke KF. The scope, presentation, and management of genitourinary complications in patients presenting with high-grade urethral complications after radiotherapy for prostate cancer. Can Urol Assoc J. 2021; 15 (1): E 6–E 10. doi: 10.5489/cuaj.6599Doiron RC, Witten J, Rourke KF. The scope, presentation, and management of genitourinary complications in patients presenting with high-grade urethral complications after radiotherapy for prostate cancer. Can Urol Assoc J. 2021; 15 (1): E 6–E 10. doi: 10.5489/cuaj.6599David RV, Islam A, Miller J. et al. Genitourinary toxicity after pelvic radiation : prospective review of complex urological presentations. Asian J Urol. 2024; 11 (4): 633–641. doi: 10.1016/j.ajur.2023.01.006David RV, Islam A, Miller J. et al. Genitourinary toxicity after pelvic radiation : prospective review of complex urological presentations. Asian J Urol. 2024; 11 (4): 633–641. doi: 10.1016/j.ajur.2023.01.006Gatsinga R, Lim BJH, Kumar N. et al. Radiation-induced hemorrhagic cystitis in prostate cancer survivors: the hidden toll. Medicina (Kaunas). 2024; 60 (11): 1746. doi: 10.3390/medicina60111746Gatsinga R, Lim BJH, Kumar N. et al. Radiation-induced hemorrhagic cystitis in prostate cancer survivors: the hidden toll. Medicina (Kaunas). 2024; 60 (11): 1746. doi: 10.3390/medicina60111746Li X, Shan L, Wang Q. et al. Comparison of chronic gastrointestinal and genito-urinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer : a systematic review and meta-analysis. Technol Health Care. 2023; 31 (S 1): 357–372. doi: 10.3233/THC-236031Li X, Shan L, Wang Q. et al. Comparison of chronic gastrointestinal and genito-urinary toxicities between brachytherapy and external beam radiotherapy for patients with prostate cancer : a systematic review and meta-analysis. Technol Health Care. 2023; 31 (S 1): 357–372. doi: 10.3233/THC-236031Tward JD, Jarosek S, Chu H. et al. Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2016; 95 (5): 1443–1453. doi: 10.1016/j.ijrobp.2016.03.047Tward JD, Jarosek S, Chu H. et al. Time course and accumulated risk of severe urinary adverse events after high- versus low-dose-rate prostate brachytherapy with or without external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2016; 95 (5): 1443–1453. doi: 10.1016/j.ijrobp.2016.03.047Gill S, Thomas J, Fox C. et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6: 145. doi: 10.1186/1748-717X-6-145Gill S, Thomas J, Fox C. et al. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy. Radiat Oncol. 2011; 6: 145. doi: 10.1186/1748-717X-6-145Сафронова Е. В. Оценка степени острой местной токсичности при лечении рака предстательной железы радикальным методом лучевой терапии с модуляцией интенсивности дозы при разных режимах фракционирования. Онкологический журнал. 2016; 10 (1 (37)): 55–58.Safronova E. V. Assessment of the degree of acute local toxicity in the treatment of prostate cancer by radical radiation therapy with dose intensity modulation in different fractionation regimens. Oncological journal. 2016; 10 (1 (37)): 55–58. (In Russ.).Baskin A, Cowan JE, Braun A, et al. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Urol Oncol. 2023; 41(10): 429.e9–429.e14. doi: 10.1016/j.urolonc.2023.06.003Baskin A, Cowan JE, Braun A, et al. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Urol Oncol. 2023; 41(10): 429.e9–429.e14. doi: 10.1016/j.urolonc.2023.06.003Киреева Т. А., Гуменецкая Ю. В., Бирюков В. А. и др. Оценка токсичности лечения при профилактическом облучении лимфатических узлов малого таза у больных раком предстательной железы высокого риска прогрессирования. Онкология. Журнал им. П. А. Герцена. 2022; 11 (2): 20–24. doi: 10.17116/onkolog20221102120Kireeva T. A., Gumenetskaya Yu.V., Biryukov V. A. and others. Assessment of the toxicity of treatment with prophylactic irradiation of pelvic lymph nodes in patients with prostate cancer at high risk of progression. Oncology. P. A. Herzen Magazine. 2022; 11 (2): 20–24. (In Russ.). doi: 10.17116/onkolog20221102120Sutani S, Ohashi T, Sakayori M. et al. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Radiother Oncol. 2015; 117 (2): 270–6. doi: 10.1016/j.radonc.2015.08.019Sutani S, Ohashi T, Sakayori M. et al. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy. Radiother Oncol. 2015; 117 (2): 270–6. doi: 10.1016/j.radonc.2015.08.019Inokuchi H, Mizowaki T, Norihisa Y. et al. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: a 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol. 2017; 6: 31–36. doi: 10.1016/j.ctro.2017.09.005Inokuchi H, Mizowaki T, Norihisa Y. et al. Correlation between urinary dose and delayed radiation cystitis after 78 Gy intensity-modulated radiotherapy for high-risk prostate cancer: a 10-year follow-up study of genitourinary toxicity in clinical practice. Clin Transl Radiat Oncol. 2017; 6: 31–36. doi: 10.1016/j.ctro.2017.09.005Shinde A, Li R, Han C, Frankel P. et al. Dosimetric predictors of genitourinary toxicity from a phase i trial of prostate bed stereotactic body radiation therapy. Pract Radiat Oncol. 2021; 11 (1): e90–e97. doi: 10.1016/j.prro.2020.06.004.Shinde A, Li R, Han C, Frankel P. et al. Dosimetric predictors of genitourinary toxicity from a phase i trial of prostate bed stereotactic body radiation therapy. Pract Radiat Oncol. 2021; 11 (1): e90–e97. doi: 10.1016/j.prro.2020.06.004.Сидорова С. А., Школьник М. И., Богомолов О. А. и др. Частота лучевых повреждений у больных раком предстательной железы, получивших комбинированное гормонолучевое лечение после закрытия эпицистостомы. Ученые записки СПбГМУ ИМ. акад. И. П. Павлова. 2015; XXII (03): 51–53.Sidorova S. A., Shkolnik M. I., Bogomolov O. A. and others. The frequency of radiation injuries in patients with prostate cancer who received combined hormone radiation treatment after epicystostomy closure. Scientific notes of Pavlov St. Petersburg State Medical University. 2015; XXII (03): 51–53. (In Russ.).Massi MC, Gasperoni F, Ieva F. et al. A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE multi-national cohort. Front Oncol. 2020; 10: 541281. doi: 10.3389/fonc.2020.541281Massi MC, Gasperoni F, Ieva F. et al. A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE multi-national cohort. Front Oncol. 2020; 10: 541281. doi: 10.3389/fonc.2020.541281Шуленина Л. В., Михайлов В. Ф., Раева Н. Ф. и др. МикроРНК в крови пациентов с раком предстательной железы как возможный показатель ранних осложнений лучевой терапии. Радиационная биология. Радиоэкология. 2017; 57 (6): 598–607.Shulenina L. V., Mikhailov V. F., Raeva N. F. and others. microRNAs in the blood of patients with prostate cancer as a possible indicator of early complications of radiation therapy. Radiation biology. Radioecology. 2017; 57 (6): 598–607. (In Russ.).Корытов О. В., Корытова Л. И., Григорьев С. Г. Исследование рисков возникновения лучевых реакций у пациентов, получающих облучение органов малого таза. Российский биотерапевтический журнал. 2024; 23 (2): 69–77. doi: 10.17650/1726-9784-2024-23-2-69-77Korytov O. V., Korytova L. I., Grigoriev S. G. Investigation of the risks of radiation reactions in patients receiving pelvic radiation. Russian Biotherapeutic Journal. 2024; 23 (2): 69–77. (In Russ.). doi: 10.17650/1726-9784-2024-23-2-69-77Neckonoff E, Anderson CB. Advancements in understanding and managing radiation cystitis : a comprehensive review. Curr Urol Rep. 2024; 26 (1): 1. doi: 10.1007/s11934-024-01238-0Neckonoff E, Anderson CB. Advancements in understanding and managing radiation cystitis : a comprehensive review. Curr Urol Rep. 2024; 26 (1): 1. doi: 10.1007/s11934-024-01238-0Chargari C, Supiot S, Hennequin C. et al. Treatment of radiation-induced late effects: what’s new? Cancer Radiother. 2020; 24 (6–7): 602–611. doi: 10.1016/j.canrad.2020.06.007.S1278-3218(20)30177-3Chargari C, Supiot S, Hennequin C. et al. Treatment of radiation-induced late effects: what’s new? Cancer Radiother. 2020; 24 (6–7): 602–611. doi: 10.1016/j.canrad.2020.06.007.S1278-3218(20)30177-3Boström M, Kalm M, Eriksson Y. et al. A role for endothelial cells in radiation-induced inflammation. Int J Radiat Biol. 2018; 94 (3): 259–271. doi: 10.1080/09553002.2018.1431699Boström M, Kalm M, Eriksson Y. et al. A role for endothelial cells in radiation-induced inflammation. Int J Radiat Biol. 2018; 94 (3): 259–271. doi: 10.1080/09553002.2018.1431699Venkatesulu B., Mahadevan L., Aliru M. Radiation-induced endothelial vascular injury : a review of possible mechanisms. JACC Basic Trans Science. 2018; 3 (4): 563–572. doi: 10.1016/j.jacbts.2018.01.014Venkatesulu B., Mahadevan L., Aliru M. Radiation-induced endothelial vascular injury : a review of possible mechanisms. JACC Basic Trans Science. 2018; 3 (4): 563–572. doi: 10.1016/j.jacbts.2018.01.014Стрельцова О. С., Моисеев А. А., Киселева Е. Б. и др. Оперативная прижизненная оценка состояния соединительной ткани мочевого пузыря в возможности прогнозирования тяжести лучевого поражения. Экспериментальная и клиническая урология. 2018; (4): 40–45.Streltsova O. S., Moiseev A. A., Kiseleva E. B. and others. Operative lifetime assessment of the condition of the connective tissue of the bladder in the possibility of predicting the severity of radiation damage. Experimental and clinical urology. 2018; (4): 40–45. (In Russ.).Бердичевский В. Б., Гутрова Е. И., Хилькевич С. В. и др. Клинико-морфологические особенности проявления хронического бактериального, лучевого и БЦЖ-индуцированного цистита. Медицинский вестник Башкортостана. 2022; 17 (4 (100)): 22–25.Berdichevsky V. B., Gutrova E. I., Khilkevich S. V. and others. Clinical and morphological features of the manifestation of chronic bacterial, radiation and BCG-induced cystitis. Medical Bulletin of Bashkortostan. 2022; 17 (4 (100)): 22–25. (In Russ).Helissey C, Cavallero S, Mondot S. et al. Correlation between serum and urine biomarkers and the intensity of acute radiation cystitis in patients treated with radiation therapy for localized prostate cancer: Protocol for the Radiotoxicity Bladder Biomarkers (RABBIO) study. JMIR Res Protoc. 2023; 12: e38362. doi: 10.2196/38362Helissey C, Cavallero S, Mondot S. et al. Correlation between serum and urine biomarkers and the intensity of acute radiation cystitis in patients treated with radiation therapy for localized prostate cancer: Protocol for the Radiotoxicity Bladder Biomarkers (RABBIO) study. JMIR Res Protoc. 2023; 12: e38362. doi: 10.2196/38362Meziani L, Deutsch E, Mondini M. Macrophages in radiation injury: a new therapeutic target. OncoImmunology. 2018; 7 (10): e1494488. doi: 10.1080/2162402x.2018.1494488Meziani L, Deutsch E, Mondini M. Macrophages in radiation injury: a new therapeutic target. OncoImmunology. 2018; 7 (10): e1494488. doi: 10.1080/2162402x.2018.1494488Foro P, Algara M, Lozano J. et al. Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study. Int J Radiat Oncol Biol Phys. 2014; 88 (5): 1057–1063. doi: 10.1016/j.ijrobp.2014.01.002.S0360-3016(14)00005-4Foro P, Algara M, Lozano J. et al. Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study. Int J Radiat Oncol Biol Phys. 2014; 88 (5): 1057–1063. doi: 10.1016/j.ijrobp.2014.01.002.S0360-3016(14)00005-4Zwaans BMM, Nicolai HE, Chancellor MB. et al. Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. PLoS One. 2020; 15 (10): e0241388. doi: 10.1371/journal.pone.0241388Zwaans BMM, Nicolai HE, Chancellor MB. et al. Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. PLoS One. 2020; 15 (10): e0241388. doi: 10.1371/journal.pone.0241388Zwaans BMM, Bartolone SN, Chancellor MB. et al. Altered angiogenic growth factors in urine of prostate cancer survivors with radiation history and radiation cystitis. Urology. 2018; 120: 180–186. doi: 10.1016/j.urology.2018.07.025Zwaans BMM, Bartolone SN, Chancellor MB. et al. Altered angiogenic growth factors in urine of prostate cancer survivors with radiation history and radiation cystitis. Urology. 2018; 120: 180–186. doi: 10.1016/j.urology.2018.07.025Lojanapiwat B, Sripralakrit S, Soonthornphan S, et al. Intravesicle formalin instillation with a modified technique for controlling haemorrhage secondary to radiation cystitis. Asian J Surg. 2002; 25 (3): 232–5. doi: 10.1016/S1015-9584(09)60181-0Lojanapiwat B, Sripralakrit S, Soonthornphan S, et al. Intravesicle formalin instillation with a modified technique for controlling haemorrhage secondary to radiation cystitis. Asian J Surg. 2002; 25 (3): 232–5. doi: 10.1016/S1015-9584(09)60181-0Терехов О. В., Пасов В. В. Лечение поздних лучевых повреждений мочевого пузыря. Эффективная фармакотерапия. 2014; (32): 26–31.TerTerekhov O.V., Pasov V. V. Treatment of late radiation injuries of the bladder. Effective pharmacotherapy. 2014; (32): 26–31. (In Russ.).Redorta JP, Sanguedolce F, Pardo GS. et al. Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): a randomised controlled study. Eur Urol Open Sci. 2021; 26: 45–54. doi: 10.1016/j.euros.2021.01.016Redorta JP, Sanguedolce F, Pardo GS. et al. Multicentre International Study for the Prevention with iAluRil of Radio-induced Cystitis (MISTIC): a randomised controlled study. Eur Urol Open Sci. 2021; 26: 45–54. doi: 10.1016/j.euros.2021.01.016Gacci M, Saleh O, Giannessi C. et al. Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urol. 2015; 15: 65. doi: 10.1186/s12894-015-0046-1Gacci M, Saleh O, Giannessi C. et al. Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study. BMC Urol. 2015; 15: 65. doi: 10.1186/s12894-015-0046-1Кульченко Н. Г. Медикаментозное лечение осложнений после лучевой терапии. Исследования и практика в медицине. 2018; 5 (S 1): 52.Kulchenko N. G. Medical treatment of complications after radiation therapy. Research and practice in medicine. 2018; 5 (S 1): 52. (In Russ.).Каприн А. Д., Титова В. А., Иванов С. А. и др. Системная и внутрипузырная озонотерапия при циститах после радикальной лучевой терапии и комплексного лечения злокачественных опухолей малого таза. Онкоурология. 2006; (4): 35–37.Kaprin A. D., Titova V. A., Ivanov S. A. and others. Systemic and intravesical ozone therapy for cystitis after radical radiation therapy and complex treatment of malignant tumors of the small pelvis. Oncourology. 2006; (4): 35–37. (In Russ.).Hamilton K, Bennett NC, Purdie G. et al. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo-controlled pilot study. Support Care Cancer. 2015; 23(1): 95–102. doi: 10.1007/s00520-014-2335-8Hamilton K, Bennett NC, Purdie G. et al. Standardized cranberry capsules for radiation cystitis in prostate cancer patients in New Zealand: a randomized double blinded, placebo-controlled pilot study. Support Care Cancer. 2015; 23(1): 95–102. doi: 10.1007/s00520-014-2335-8Herst PM, Aumata A, Sword V. et al. Cranberry capsules are not superior to placebo capsules in managing acute non-haemorrhagic radiation cystitis in prostate cancer patients: a phase III double blinded randomised placebo controlled clinical trial. Radiother Oncol. 2020; 149: 117–123. doi: 10.1016/j.radonc.2020.05.006Herst PM, Aumata A, Sword V. et al. Cranberry capsules are not superior to placebo capsules in managing acute non-haemorrhagic radiation cystitis in prostate cancer patients: a phase III double blinded randomised placebo controlled clinical trial. Radiother Oncol. 2020; 149: 117–123. doi: 10.1016/j.radonc.2020.05.006Лоран О. Б., Синякова Л. А., Митрохин А. А. и др. Гипербарическая оксигенация в лечении поздних постлучевых циститов. Экспериментальная и клиническая урология. 2010; (2): 73–77.Laurent O. B., Sinyakova L. A., Mitrokhin A. A. and others. Hyperbaric oxygenation in the treatment of late post-radiation cystitis. Experimental and clinical urology. 2010; (2): 73–77. (In Russ.).Lin ZC, Bennett MH, Hawkins GC. et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023 15; 8 (8): CD 005005. doi: 10.1002/14651858.CD005005.pub5Lin ZC, Bennett MH, Hawkins GC. et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023 15; 8 (8): CD 005005. doi: 10.1002/14651858.CD005005.pub5Sarrió-Sanz P, Sanchez-Caballero L, Martinez-Cayuelas L. et al. Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis. Arch Esp Urol. 2022; 75 (4): 354–360. doi: 10.56434/j.arch.esp.urol.20227504.50Sarrió-Sanz P, Sanchez-Caballero L, Martinez-Cayuelas L. et al. Efficacy, tolerance and predictors of response to the treatment with hyperbaric oxygen therapy for patients with hemorrhagic radiation cystitis. Arch Esp Urol. 2022; 75 (4): 354–360. doi: 10.56434/j.arch.esp.urol.20227504.50Dellis A, Papatsoris A, Kalentzos V. et al. Hyberbaric oxygen as sole treatment for severe radiation – induced haemorrhagic cystitis. Int Braz J Urol. 2017; 43 (3): 489–495. doi: 10.1590/S1677-5538.IBJU.2016.0451Dellis A, Papatsoris A, Kalentzos V. et al. Hyberbaric oxygen as sole treatment for severe radiation – induced haemorrhagic cystitis. Int Braz J Urol. 2017; 43 (3): 489–495. doi: 10.1590/S1677-5538.IBJU.2016.0451Gaio-Lima C, Castedo J, Cruz M. et al. The role of hyperbaric oxygen therapy in the treatment of radiation lesions. Clin Transl Oncol. 2022; 24 (12): 2466–2474. doi: 10.1007/s12094-022-02892-xGaio-Lima C, Castedo J, Cruz M. et al. The role of hyperbaric oxygen therapy in the treatment of radiation lesions. Clin Transl Oncol. 2022; 24 (12): 2466–2474. doi: 10.1007/s12094-022-02892-xCardinal J, Slade A, McFarland M. et al. Scoping review and meta-analysis of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. Curr Urol Rep. 2018; 19 (6): 38. doi: 10.1007/s11934-018-0790-3Cardinal J, Slade A, McFarland M. et al. Scoping review and meta-analysis of hyperbaric oxygen therapy for radiation-induced hemorrhagic cystitis. Curr Urol Rep. 2018; 19 (6): 38. doi: 10.1007/s11934-018-0790-3Oscarsson N, Müller B, Rosén A. et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019; 20 (11): 1602–1614. doi: 10.1016/S1470-2045(19)30494-2Oscarsson N, Müller B, Rosén A. et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial. Lancet Oncol. 2019; 20 (11): 1602–1614. doi: 10.1016/S1470-2045(19)30494-2Ravi R. Endoscopic neodymium: YAG laser treatment of radiation-induced hemorrhagic cystitis. Lasers Surg Med. 1994; 14 (1): 83–7. doi: 10.1002/lsm.1900140116.Ravi R. Endoscopic neodymium: YAG laser treatment of radiation-induced hemorrhagic cystitis. Lasers Surg Med. 1994; 14 (1): 83–7. doi: 10.1002/lsm.1900140116.Talab SS, McDougal WS, Wu CL. et al. Mucosa-sparing, KTP laser coagulation of submucosal telangiectatic vessels in patients with radiation-induced cystitis: a novel approach. Urology. 2014; 84 (2): 478–83. doi: 10.1016/j.urology.2014.03.029Talab SS, McDougal WS, Wu CL. et al. Mucosa-sparing, KTP laser coagulation of submucosal telangiectatic vessels in patients with radiation-induced cystitis: a novel approach. Urology. 2014; 84 (2): 478–83. doi: 10.1016/j.urology.2014.03.029Zhu J, Xue B, Shan Y. et al. Transurethral coagulation for radiation-induced hemorrhagic cystitis using Greenlight™ potassium-titanyl-phosphate laser. Photomed Laser Surg. 2013; 31 (2): 78–81. doi: 10.1089/pho.2012.3396Zhu J, Xue B, Shan Y. et al. Transurethral coagulation for radiation-induced hemorrhagic cystitis using Greenlight™ potassium-titanyl-phosphate laser. Photomed Laser Surg. 2013; 31 (2): 78–81. doi: 10.1089/pho.2012.3396Martinez DR, Ercole CE, Lopez JG. et al. A novel approach for the treatment of radiation-induced hemorrhagic cystitis with the GreenLightTM XPS Laser. Int Braz J Urol. 2015; 41 (3): 584–7. doi: 10.1590/S1677–5538Martinez DR, Ercole CE, Lopez JG. et al. A novel approach for the treatment of radiation-induced hemorrhagic cystitis with the GreenLightTM XPS Laser. Int Braz J Urol. 2015; 41 (3): 584–7. doi: 10.1590/S1677–5538Principles and Practice of Radiation Oncology (seventh edition) / eds. E. C. Halperin, D. E. Wazer, C. A. Perez, L. W. Brady. Wolters Kluwer, Philadelphia; 2019. Chapter 69–70. P. 1560–1622.Principles and Practice of Radiation Oncology (seventh edition) / eds. E. C. Halperin, D. E. Wazer, C. A. Perez, L. W. Brady. Wolters Kluwer, Philadelphia; 2019. Chapter 69–70. P. 1560–1622.

The authors declare that there are no conflicts of interest present.